Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea–hypnoea index (AHI)

INTRODUCTION: Obstructive sleep apnoea (OSA) and type 2 diabetes mellitus (T2DM) often occur concurrently, and untreated OSA may potentially amplify the high risk of cardiovascular disease in T2DM. Compliance with continuous positive airway pressure (CPAP), the conventional treatment for OSA, can be...

Descripción completa

Detalles Bibliográficos

Autores principales:	Sprung, Victoria S, Kemp, Graham J, Wilding, John PH, Adams, Valerie, Murphy, Kieran, Burgess, Malcolm, Emegbo, Stephen, Thomas, Matthew, Needham, Alexander J, Weimken, Andrew, Schwab, Richard J, Manuel, Ari, Craig, Sonya E, Cuthbertson, Daniel J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Diabetes and Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380950/ https://www.ncbi.nlm.nih.gov/pubmed/32699168 http://dx.doi.org/10.1136/bmjopen-2020-038856